Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches

@article{Needham2007InclusionBM,
  title={Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches},
  author={Merrilee Needham and Frank L Mastaglia},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={620-631}
}

Figures from this paper

Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment

Diagnosis and classification of sporadic inclusion body myositis (sIBM).

Sporadic inclusion body myositis: an unsolved mystery.

TLDR
It remains uncertain whether sIBM is primarily an immune-mediated inflammatory myopathy or a degenerative myopathy with an associated inflammatory component.

Sporadic Inclusion Body Myositis

Sporadic inclusion body myositis (sIBM) is the most common acquired muscle disease in elderly individuals, particularly men. Its prevalence varies among ethnic groups, but it is estimated at 35 per

Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects

TLDR
Understanding the aetiopathogeneis is vital to identify future treatment targets, and understanding the natural history and the roles of biomarkers including the anti-CN1a antibody is vital for designing future clinical trials in IBM.

Sporadic inclusion body myositis: an unsolved mystery 1 SPORADIC INCLUSION BODY MYOSITIS: AN UNSOLVED MYSTERY

TLDR
The epidemiology and clinical features of sIBM as well as the current genetic and pathogenic concepts and therapeutic approaches are described and it remains uncertain whether it is primarily an immune-mediated inflammatory myopathy or a degenerative myopathy with an associated inflammatory component.

Inclusion body myositis: diagnosis, pathogenesis, and treatment options.

Inclusion body myositis: therapeutic approaches. A case report.

Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

TLDR
Research suggests that categorizing heterogeneous myositis syndromes into mutually exclusive and stable phenotypes by using clinical and immune response features is useful for predicting clinical signs and symptoms, associated genetic and environmental risk factors, and responses to therapy and prognosis.
...

References

SHOWING 1-10 OF 163 REFERENCES

Inclusion body myositis: atypical clinical presentations.

TLDR
The clinical spectrum of inclusion body myositis is suggested to be wider than previously appreciated, with patients with atypical clinical presentations and associated immune-mediated diseases.

Inclusion body myositis.

TLDR
The typical distribution of muscle weakness, poor response to immunosuppressive treatment, pathological accumulation of various proteins in vacuolated muscle fibres, inflammatory reaction and mitochondrial changes have all been subjects of recent research that has led to better understanding of the pathogenic events that leads to muscle degeneration and weakness.

Inclusion body myositis.

TLDR
Inclusion body myositis is an inflammatory myopathy with distinctive clinicopathologic features and the immune-mediated basis for this disease has been challenged by evidence implicating a number of divergent etiologic factors.

Polymyositis, dermatomyositis and inclusion-body myositis.

  • M. Dalakas
  • Medicine
    The New England journal of medicine
  • 1991
TLDR
The evolution over the past 10 years of rather well defined clinical, demographic, histologic, and immunopathological criteria and the identification of inclusion-body myositis as a distinct type of polymyositis now means the inflammatory myopathies now are considered to be pathogenetically similar.

Inclusion body myositis long after dermatomyositis: a report of two cases.

TLDR
Two patients who first developed dermatomyositis, and then, after a disease-free interval of many years, developed inclusion body myositis are reported.

Inclusion body myositis long after dermatomyositis: a report of two cases.

TLDR
Two patients who first developed dermatomyositis, and then, after a disease-free interval of many years, developed inclusion body myositis are reported.

Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects

TLDR
Improved understanding of the molecular mechanisms of muscle injury in the inflammatory myopathies should lead to the development of more specific forms of immunotherapy for these conditions.

Inclusion body myositis

TLDR
While inflammation decreased in the muscle biopsy specimens, the number of vacuolated and amyloid-positive fibers increased after oral prednisone therapy, indicating that the inflammatory response in IBM may play a secondary role in the pathogenesis of IBM.

Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies

  • M. Dalakas
  • Biology, Medicine
    Nature Clinical Practice Neurology
  • 2006
TLDR
Emerging data imply that continuous upregulation of cytokines and major histocompatibility complex class I on the muscle fibers causes an endoplasmic reticulum stress response, resulting in intracellular accumulation of misfolded glycoproteins and activation of the transcription factor NFκB, leading to further cytokine activation.

A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups

TLDR
Myositis-specific autoantibody status is a more useful guide than clinical group in assessing patients with myositis, and that specific associations of immunogenetics, immune responses, and clinical manifestations occur in IIM.
...